Document is current
Any future updates will be listed below
-
Authors
Perez-Bermejo, Juan A.
Judge, Luke M.
Jensen, Christina L.
Wu, Kenneth
Watry, Hannah L.
Truong, Annie
Ho, Jaclyn J. https://orcid.org/0000-0001-9166-5953
Carter, Matthew https://orcid.org/0000-0003-1705-0090
Runyon, Wendy V.
Kaake, Robyn M.
Pulido, Ernst H. https://orcid.org/0000-0002-3616-9743
Mandegar, Mohammad A.
Swaney, Danielle L.
So, Po-Lin
Krogan, Nevan J. https://orcid.org/0000-0003-4902-337X
Conklin, Bruce R. https://orcid.org/0000-0003-1463-6061
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01-HL130533, R01-HL13535801, F32AI127291, P01 HL146366)
Roddenberry Foundation
Bristol-Myers Squibb Foundation (63376)
California Institute for Regenerative Medicine (TG2-01160)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (1K12HD072222)
- License Information
-
More Information
Article History
Received: 17 October 2021
Accepted: 18 May 2023
First Online: 26 June 2023
Competing interests
: B.R.C. is a founder of Tenaya Therapeutics (), a company focused on finding treatments for heart failure, including genetic cardiomyopathies. B.R.C. and J.J.H. hold equity in Tenaya Therapeutics. The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. N.J.K. has a consulting agreements with the Icahn School of Medicine at Mount Sinai. He is a shareholder of Tenaya Therapeutics, Maze Therapeutics and Interline Therapeutics. The remaining authors declare no competing interests.
